New diabetes drug HRS-7535 shows promise in early trial

NCT ID NCT06393348

Completed Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested a new drug called HRS-7535 in 155 adults with type 2 diabetes whose blood sugar was not well controlled despite taking metformin and an SGLT2i. Participants received either HRS-7535 or a placebo for 16 weeks. The main goal was to see if the drug could lower HbA1c (a measure of average blood sugar) more than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-7535
What this could lead to: If it works, this could offer a new oral medication option to help people with type 2 diabetes better control their blood sugar and possibly lose weight.
What could go wrong: This is an early Phase 2 trial with only 155 people, so results may not apply to everyone. The drug may not prove effective or could have side effects not yet seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

The Sun Yat-sen Memorial Hospital of Sun Yat-sen University

Guangdong, Guangzhou, 51020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.